Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone. Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 antagonist is more effective than aspirin monotherapy in prevention of thrombosis, but at the cost of more bleeding. Although the CHARISMA trial did not find a benefit of adding clopidogrel to aspirin in its overall study cohort, a benefit was suggested in a.
Dual Anti-Platelet Therapy in Stable Ischemic Heart Disease. Patients at hher risk for thrombotic events, such as those with acute coronary syndromes (ACS) or a recent percutaneous coronary intervention (PCI), benefit from DAPT as its reduction in ischemic events outwehs its increase in bleeding risk. Dual anti-platelet therapy DAPT with aspirin and a P2Y12. and Avoidance CHARISMA trial.5 CHARISMA randomized over 15,000 patients with. aspirin plus clopidogrel or aspirin monotherapy showed no difference in a.
CHARISMA The Antiplatelet Saga Continues Stroke To determine the incremental cost-effectiveness of clopidogrel plus aspirin (C A) compared with aspirin (A) alone during the Clopidogrel for Hh Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial from a US payer perspective. The CHARISMA trial showed that clopidogrel plus low-dose aspirin was not more effective than aspirin alone in reducing the rate of vascular events in patients.
Charisma plavix and aspirin:
Rating: 97 / 100
Overall: 91 Rates